## The cancer cell 'energy grid':  $TGF- $\beta$ 1 signaling coordinates metabolism$ for migration

Lei Jiang<sup>1</sup>, Ralph Deberardinis<sup>1</sup>, and David A Boothman<sup>2,\*</sup>

<sup>1</sup>Children's Medical Center Research Institute; University of Texas Southwestern Medical Center; Dallas, TX USA; <sup>2</sup>Departments of Pharmacology and Radiation Oncology; University of Texas Southwestern Medical Center; Dallas, TX USA

Keywords: Epithelial-to-Mesenchymal Transition, fatty acid synthase, lipogenesis, metastasis, transforming growth factor  $beta 1$  (TGF $\beta$ 1)

© Lei Jiang, Ralph Deberardinis, and David A Boothman

\*Correspondence to: David A Boothman; Email: David.Boothman@UTSouthwestern.edu

Submitted: 10/24/2014

Revised: 10/24/2014

Accepted: 10/27/2014

http://dx.doi.org/10.4161/23723556.2014.981994

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License ([http://creativecommons.org/](http://creativecommons.org/licenses/by-nc/3.0/) [licenses/by-nc/3.0/\), which permits unrestricted](http://creativecommons.org/licenses/by-nc/3.0/) [non-commercial use, distribution, and reproduction](http://creativecommons.org/licenses/by-nc/3.0/) [in any medium, provided the original work is prop](http://creativecommons.org/licenses/by-nc/3.0/)[erly cited. The moral rights of the named author\(s\)](http://creativecommons.org/licenses/by-nc/3.0/) [have been asserted.](http://creativecommons.org/licenses/by-nc/3.0/)

Cancer cells have an increased reli-<br>
ance on lipogenesis, which is required for uncontrolled cell division. We recently reported transcriptional and functional 'reprogramming' of the cellular energy grid, allowing cancer cells to divert metabolism from biosynthesis to bioenergetic pathways and thus supplying enhanced mobility during epithelial–mesenchymal transition (EMT) induced by transforming growth factor  $\beta$  (TGF- $\beta$ 1) (Fig. 1).

Unlike most differentiated non-proliferating cells, cancer cells tend to display a high glycolytic rate regardless of the presence or absence of oxygen, a phenomenon known as the 'Warburg effect'. Cancer cells use glycolysis for energy and to generate building blocks for cell division.<sup>1</sup> Lipids, amino acids, and nucleotides are the 3 basic elements required for proliferation. Lipogenesis is commonly achieved by increased de novo fatty acid synthesis to support rapid cell membrane growth. $\frac{2}{x}$ 

Although primary tumors can be removed by surgery, metastatic disease is the major cause of death for most cancers, and particularly breast and lung carcinomas. To date, most findings on cancer metabolism have been derived from primary tumors and cancer cell lines. Although metabolism has been studied in  $vivo$  in gliomas<sup>3</sup>, these tumors do not typically metastasize and therefore do not instruct about metabolic transitions that may accompany the acquisition of metastatic capacity. The major focus of our studies is stromal–tumor microenvironmental interactions that affect cancer metabolism. Using a transforming growth factor  $\beta$ 1 (TGF- $\beta$ 1)-induced epithelialmesenchymal transition (EMT) model,

we found a metabolic profile in migrating cells that differs from that in rapidly proliferating cells.<sup>4</sup> TGF- $\beta$ 1 exposure of A549 non-small cell lung cancer (NSCLC) cells, which induced an EMT, resulted in coordinated transcriptional suppression of lipogenic enzymes, including fatty acid synthase (FASN) and acetyl-CoA carboxylase (ACC). These enzymes are normally under the control of the lipogenic master transcriptional regulators carbohydrate-responsive element-binding protein (ChREBP) and sterol regulatory element binding proteins (SREBPs). We noted dramatic downregulation of both  $SREBPs$  and  $ChREBP$  during TGF- $\beta$ 1induced EMT in A549 cells. SNAIL1, a well-known key transcription factor in the regulation of  $EMT$ ,<sup>5</sup> mediated suppression of this lipogenic reprogramming. In the absence of  $TGF- $\beta$ 1 treatment,$ SNAIL1 overexpression decreased lipogenesis by dramatically repressing ChREBP levels. These investigations are among the first to show the relationship between EMT and energy metabolism at a transcriptional level.

Simultaneously, Dr. Raghu Kalluri's group reported that the transcriptional coactivator peroxisome proliferator-activated receptor gamma, co-activator 1alpha (PGC-1 $\alpha$ ) promoted metastasis in an in vivo orthotopic implantation mouse model.<sup>6</sup> They found that the lipogenic enzymes Fasn and Acc were expressed at very low levels in circulating cancer cells (CCCs), compared to their higher expression profile in primary cancer cells (PCCs). Although PGC-1 $\alpha$  is known as a regulator of mitochondrial biogenesis,  $PGC-1\beta$  and ChREBP also cooperatively regulate lipogenesis in liver. However,

the interaction between PGC-1a and ChREBP has not been studied, and PGC- $1\alpha$  might indirectly control lipogenesis in cancer cells.

In addition to decreased lipogenesis, we also demonstrated higher oxygen consumption and elevated intracellular ATP levels during TGF- $\beta$ 1-induced EMT in A549 cells. Another recent study also showed that mitochondrial ATP production was crucial for cancer cell migration.<sup>8</sup> De novo fatty acid synthesis is an energyconsuming pathway, requiring large amounts of acetyl-CoA and NADPH as substrates. Decreased fatty acid synthesis could direct acetyl-CoA toward other metabolic pathways, such as the tricarboxylic acid cycle (TCA cycle) and oxidative phosphorylation, which produce energy very efficiently. This theory is consistent with the higher oxygen consumption noted during TGF- $\beta$ 1-induced EMT,

resulting in higher ATP production to fuel cell mobility, elevated migration, and increased metastatic capacity.

At the same time, using theoretical systems biology, Dr. Raphael Levine's laboratory reported energy changes during TGF-β1-induced EMT in A549 lung cancer cells.<sup>9</sup> They used single-cell ATP assays to show a dramatically increased cytosolic ATP content during EMT. Their findings are consistent with our conclusions regarding a coordinated energy switch mediated by TGF- $\beta$ 1induced EMT. Similar to TGF-B1induced EMT in A549 cells, circulating 4T1 mammary carcinoma cells favored mitochondrial respiration and increased ATP production compared to primary tumors in  $vivo$ . Thus, we hypothesize that metastatic cells reprogram metabolism from energy-consuming biosynthesis to energy-producing oxidative

phosphorylation to support the movement required for metastasis.

More importantly from a therapeutic perspective, like the reversibility of EMT and MET (mesenchymal–epithelial transition), this metabolic switch was also bidirectional. TGF- $\beta$ 1–repressed lipogenic genes, such as ChREBP, were re-expressed once  $TGF- $\beta$ 1 treatments were withdrawn.$ This reversion of the metabolic switch might be exploited for prevention of metastasis. This observation also indicates that when metastatic cells finally localize to their new predilected organ site they have the potential to switch their metabolism back to favor growth, resuming their high glycolytic and lipogenic metabolic programs.

The possibility that decreased fatty acid synthesis regulates and ultimately stimulates cell migration and metastases raises considerable caution regarding the



Figure 1. Metabolic regulation during TGF- $\beta$ 1-induced EMT. Transforming growth factor  $\beta$  (TGF- $\beta$ 1) is known to promote epithelial–mesenchymal transition (EMT) through the induction of SNAIL1. Our recent study showed decreased fatty acid synthesis after TGF-B1 treatment, which is regulated through the lipogenic transcriptional factor carbohydrate-responsive element-binding protein (ChREBP). Instead of serving as the substrate for fatty acid synthesis, acetyl-CoA is oxidized through the tricarboxylic acid cycle (TCA cycle) to generate more ATP, which supports the high energy requirement of cell mobility during TGF- $\beta$ 1-induced EMT.

targeting of lipogenesis to cure cancer. We clearly demonstrated that constitutive FASN knockdown was sufficient to induce EMT in the absence of TGF- $\beta$ 1.<sup>4</sup> Consistent with previous FASN targeting studies in cancer cells,<sup>10</sup> in which the authors stated that FASN could be a potential effective anticancer target, FASN knockdown cells grew more slowly than the non-targeted control cells in culture. However, and most importantly, these same FASN knockdown A549 cells migrated faster both in vitro and in vivo, and ultimately resulted in considerably more death through enhanced lung metastasis *in vivo*. Thus, although targeting FASN or lipogenesis might suppress growth of primary tumors, a major consequence in our model was enhanced metastasis.

In summary, like most step-wise carcinogenic processes, the growth-suppressing effects of TGF- $\beta$ 1 come with a cost—the stimulation of a metabolic transition that favors migration and metastasis. In addition to induction of an EMT transcriptional program,  $TGF- $\beta$ 1 also appears to$ 

coordinate the metabolic status. The switch from building block accumulation to free energy (ATP) production may help satisfy the energy requirement of migrating cells. Understanding this process at a molecular level should reveal valuable methods of inhibiting cancer progression and metastasis.

## References

- 1. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7:11-20.
- 2. Currie E, Schulze A, Zechner R, Walther TC, Farese RV, Jr. Cellular fatty acid metabolism and cancer. Cell Metab 2013; 18:153-61; PMID:23791484; [http://dx.](http://dx.doi.org/) [doi.org/10.1016/j.cmet.2013.05.017](http://dx.doi.org/)
- 3. Marin-Valencia I, Cho SK, Rakheja D, Hatanpaa KJ, Kapur P, Mashimo T, Jindal A, Vemireddy V, Good LB, Raisanen J, et al. Glucose metabolism via the pentose phosphate pathway, glycolysis and Krebs cycle in an orthotopic mouse model of human brain tumors. NMR Biomed 2012; 25:1177-86; PMID:22383401; http://dx.doi.org/10.1002/nbm.2787
- 4. Jiang L, Xiao L, Sugiura H, Huang X, Ali A, Kuro OM, Deberardinis RJ, Boothman DA. Metabolic reprogramming during TGFbeta1-induced epithelial-to-mesenchymal transition. Oncogene 2014; PMID: 25284588; http://dx.doi.org/10.1038/onc.2014.321
- 5. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, Nieto MA. The transcription factor snail controls epithelial-

mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2000; 2:76-83;<br>PMID:10655586; http://dx.doi.org/10.1038/ http://dx.doi.org/10.1038/ 35000025

- 6. LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, de Carvalho FM, Damascena A, Domingos Chinen LT, Rocha RM, et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol 2014; 16:992-1003; PMID:25241037; http://dx.doi.org/10.1038/ncb3039
- 7. Chambers KT, Chen Z, Lai L, Leone TC, Towle HC, Kralli A, Crawford PA, Finck BN. PGC-1beta and ChREBP partner to cooperatively regulate hepatic lipogenesis in a glucose concentration-dependent manner. Mol Metab 2013; 2:194-204; PMID:24049734; http://dx.doi.org/10.1016/j.molmet.2013.05.001
- 8. Zhou H, Zhang B, Zheng J, Yu M, Zhou T, Zhao K, Jia Y, Gao X, Chen C, Wei T. The inhibition of migration and invasion of cancer cells by graphene via the impairment of mitochondrial respiration. Biomaterials 2014; 35:1597-607; PMID:24290441; http://dx.doi. org/10.1016/j.biomaterials.2013.11.020
- 9. Zadran S, Arumugam R, Herschman H, Phelps ME, Levine RD. Surprisal analysis characterizes the free energy time course of cancer cells undergoing epithelial-to-mesenchymal transition. Proc Natl Acad Sci U S A 2014; 111:13235-40; PMID:25157127; http://dx. doi.org/10.1073/pnas.1414714111
- 10. De Schrijver E, Brusselmans K, Heyns W, Verhoeven G, Swinnen JV. RNA interference-mediated silencing of the fatty acid synthase gene attenuates growth and induces morphological changes and apoptosis of LNCaP prostate cancer cells. Cancer Res 2003; 63:3799-804; PMID:12839976